← Leaderboards
Staley Armstrong Brod
University Of Texas Hlth Sci Ctr Houston
$174,146
Attributed
$174,146
Total exposure
9
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$174,146 · 9
By mechanism
M01$174,146 · 9
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- J William Lindsey$31,806
- Barry D Kahan$1,580,007
- Hope Northrup$1,744,087
- Jerry Saul Wolinsky$26,242
- Ponnada A Narayana$19,017,319
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationInterferon AlphaImmunotherapyMultiple SclerosisClinical Trial Phase IDisease /Disorder Prevention /ControlOral AdministrationInsulin Dependent Diabetes MellitusDiabetes Mellitus TherapyNeuropsychological TestsPancreatic Islet FunctionImmunopathology ChemotherapyCognition DisordersAlzheimer'S DiseaseNervous System Disorder ChemotherapyNeuroprotectantsDrug Administration RoutesDosageLongitudinal Human StudyInterferon GammaMagnetic Resonance ImagingInterferon Beta
Grant awards (21)
IFNA: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES MELLITUS$63,239
M01 · FY2005 · RR
PROTEIN BIOMARKERS OF IFN-ALPHA IN MS$17,837
M01 · FY2005 · RR
INGESTED IFN-A: PROLONGATION OR PERMANENCE OF THE "HONEYMOON" PHASE IN DIABETES$11,351
M01 · FY2005 · RR
PREVENTION OF COGNITIVE DECLINE IN ALZHEIMER'S DISEASE VIA INGESTED IFN-ALPHA$1,622
M01 · FY2005 · RR
IFNa prolongation or permanence of the "honeymoon" in DM$17,212
M01 · FY2004 · RR
Protein biomarkers of IFN-alpha in MS$10,261
M01 · FY2004 · RR
Ingested IFN-a: Prolongation or permanence$3,972
M01 · FY2004 · RR
Prevention of cognitive decline in Alzheimer's disease$2,648
M01 · FY2004 · RR
A dose-response study of ingested IFN-a using Mx mRNA$662
M01 · FY2004 · RR
INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES$0
M01 · FY2002 · RR
AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS$0
M01 · FY2002 · RR
ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS$0
M01 · FY2002 · RR
Prevention of cognitive decline in Alzheimer's disease via interferon alpha$0
M01 · FY2002 · RR
AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
Prevention of cognitive decline in Alzheimer's disease via interferon alpha$0
M01 · FY2001 · RR
INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES$0
M01 · FY2001 · RR
ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS$0
M01 · FY2001 · RR
ORAL INTERFERON ALPHA--EFFECTS IN RELAPSING REMITTING MULTIPLE SCLEROSIS$15,114
M01 · FY2000 · RR
AVONEX (IFN B1A) IN SUBJECTS AT HIGH RISK FOR DEVELOPMENT OF MULTIPLE SCLEROSIS$15,114
M01 · FY2000 · RR
INTERFERON A--PROLONGATION OR PERMANENCE OF THE HONEYMOON PERIOD IN DIABETES$15,114
M01 · FY2000 · RR
Prevention of cognitive decline in Alzheimer's disease via interferon alpha$0
M01 · FY2000 · RR